EFFICACY OF ERLOTINIB FOR CNS RELAPSE AFTER GEFITINIB TREATMENT IN NON SMALL CELL LUNG CANCER PATIENTS

被引：0
作者：
Yanagitani, N. [1 ]
Sakatani, T. [1 ]
Saito, R. [1 ]
Tanaka, H. [1 ]
Kaburaki, K. [1 ]
Kudo, K. [1 ]
Ohyanagi, F. [1 ]
Horiike, A. [1 ]
Horai, T. [1 ]
Nishio, M. [1 ]
机构：
[1] Japanese Fdn Canc Res, Thorac Oncol Ctr, Canc Inst Hosp, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
  • [21] Erlotinib or Gefitinib for Non-Small-Cell Lung Cancer REPLY
    Cataldo, Vince D.
    Gibbons, Don L.
    Quintas-Cardama, Alfonso
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (24) : 2368 - 2368
  • [22] Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer
    Passaro, Antonio
    Alesini, Daniele
    Pochesci, Alessia
    Cortesi, Enrico
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (05) : 646 - 650
  • [23] Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?
    Vasile, E.
    Tibaldi, C.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20 (04) : 790 - 791
  • [24] Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer
    Viswanathan, A
    Pillot, G
    Govindan, R
    LUNG CANCER, 2005, 50 (03) : 417 - 418
  • [25] Erlotinib for relapsed or refractory Non-Small-Cell Lung Cancer after failure of gefitinib
    Nishihira, Ryuichi
    Ogura, Takashi
    Tajiri, Michihiko
    Kato, Terufumi
    Sekine, Akimasa
    Shinohara, Takeshi
    Baba, Tomohisa
    Takahashi, Hiroshi
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S703 - S703
  • [26] EFFECTIVENESS OF ERLOTINIB IN ADVANCED NON-SMALL-CELL LUNG CANCER AFTER FAILURE OF GEFITINIB
    Saito, Haruhiro
    Murakami, Shuji
    Honda, Takeshi
    Kondo, Tetsuro
    Oshita, Fumihiro
    Noda, Kazumasa
    Yamada, Kouzo
    ANNALS OF ONCOLOGY, 2010, 21 : 26 - 26
  • [27] Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment: Is there a rationale for a clinical trial?
    Salesi, Nello
    Di Cocco, Barbara
    Calabretta, Francesca
    Ciorra, Alida Armida
    Cirino, Crescenzo
    Cauchi, Carolina
    Pistillucci, Giorgio
    Sciacca, Venerina
    Rossi, Rosalinda
    Veltri, Enzo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer
    Fujiwara, Atsushi
    Yoshida, Masamichi
    Fujimoto, Hajime
    Nakahara, Hiroki
    Ito, Kentaro
    Nishihama, Kota
    Yasuma, Taro
    Hataji, Osamu
    Taguchi, Osamu
    D'Alessandro-Gabazza, Corina N.
    Gabazza, Esteban C.
    Kobayashi, Tetsu
    ONCOLOGY RESEARCH, 2018, 26 (07) : 1031 - 1036
  • [29] Efficacy and Toxicity of Erlotinib and Gefitinib in Moroccan Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation
    Benchakroun, N.
    Minoungou, N.
    Bouchbika, Z.
    Jouhadi, H.
    Tawfik, N.
    Sahraoui, S.
    Benider, A.
    Acharki, A.
    Lemzah, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S953 - S953
  • [30] Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer
    Rossi, Antonio
    La Salvia, Anna
    Di Maio, Massimo
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2017, 11 (03) : 171 - 180
12345